Wockhardt reported rise of 4.61% in top line sales for the Sep-20 quarter at Rs714.05cr. The sales in the Jun-20 quarter did dip by 12% but that has been recouped in September. The company also has massive orders to manufacture the COVID vaccine once approved.
The operating loss for the quarter ended Sep-20 was marginally higher on a yoy basis at Rs40.45cr. The net profits for the Sep-20 quarter turned around to profit at Rs3.29cr on the back of Rs88.40cr of deferred and current tax credits.
This had an overall impact on the margins of Wockhardt Pharma. For the Sep-20 quarter, the operating profit margins improved marginally from -5.81% last year to -5.66% in Sep-20. Net margins or NPM actually turned around from -17% in Sep-19 quarter to marginally positive at 0.46% in Sep-20 on the back of tax credits to the tune of Rs88cr.
Financial highlights for Sep-20 compared yoy and sequentially
|
|
Wockhardt |
|
|
|
|
|
Rs in Crore |
Sep-20 |
Sep-19 |
YOY |
Jun-20 |
QOQ |
|
Revenues |
714.05 |
682.59 |
4.61% |
598.27 |
19.35% |
|
Operating Profit |
-40.45 |
-39.65 |
Not Relevant |
-128.01 |
Not Relevant |
|
Net Profits |
3.29 |
-116.33 |
Not Relevant |
-225.58 |
Not Relevant |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
0.32 |
-9.42 |
|
-20.34 |
|
|
OPM |
-5.66% |
-5.81% |
|
-21.40% |
|
|
Net Margins |
0.46% |
-17.04% |
|
-37.71% |
|
Related Tags: